HCA
HCA Healthcare, Inc.
NYSE · Healthcare · Medical - Care Facilities · US
$406.46
−0.67%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 78.0B | 75.6B | 70.6B | 65.0B | 60.2B |
| Cost of Revenue | 55.9B | 44.2B | 41.9B | 39.4B | 37.1B |
| Gross Profit | 22.1B | 31.4B | 28.7B | 25.6B | 23.2B |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 16.6B | 8.0B | 31.2B | 29.5B | 27.7B |
| General & Admin Expense | — | 8.0B | 31.2B | 29.5B | 27.7B |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (6.5B) | 11.4B | (13.0B) | (13.5B) | (13.6B) |
| Total Operating Expenses | 10.0B | 19.4B | 18.1B | 16.0B | 14.1B |
| Cost and Expenses | 65.9B | 63.6B | 60.1B | 55.3B | 51.2B |
| Operating Income (EBIT) | 12.1B | 12.0B | 10.5B | 9.6B | 9.1B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 2.3B | 2.2B | 2.1B | 1.9B | 1.7B |
| Net Interest Income | (2.3B) | (2.2B) | (2.1B) | (1.9B) | (1.7B) |
| Other Non-Op Income/Expense | (2.2B) | (2.1B) | (2.0B) | (1.9B) | (473.0M) |
| Non-Operating Income (excl Interest) | (88.0M) | (115.0M) | (37.0M) | (17.0M) | (1.3B) |
| EBT (Pre-Tax Income) | 9.9B | 9.8B | 8.5B | 7.7B | 8.6B |
| Income Tax Expense | 2.0B | 2.0B | 1.9B | 1.6B | 1.7B |
| Bottom Line | |||||
| Net Income | 6.8B | 6.8B | 5.8B | 5.2B | 5.6B |
| Earnings from Cont. Ops | 7.9B | 7.8B | 6.7B | 6.1B | 6.8B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 6.8B | 6.8B | 5.8B | 5.2B | 5.6B |
| Per Share | |||||
| Basic EPS | $29.96 | $28.62 | $22.27 | $19.24 | $19.44 |
| Diluted EPS | $29.87 | $28.38 | $22.00 | $18.96 | $19.15 |
| Revenue Per Share | $350.10 | $327.68 | $273.02 | $238.50 | $207.45 |
| Shares | |||||
| Basic Shares Outstanding | 222.8M | 230.7M | 258.6M | 272.4M | 290.3M |
| Diluted Shares Outstanding | 222.8M | 230.7M | 261.8M | 276.4M | 294.7M |
| Profitability Metrics | |||||
| EBITDA | 15.8B | 15.6B | 13.9B | 12.7B | 13.3B |
| D&A | 3.7B | 3.5B | 3.3B | 3.1B | 3.0B |
| EBIT | 12.2B | 12.1B | 10.6B | 9.6B | 10.3B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026